Welcome to Sabbiotech!     
Email:info@signalwayantibody.com
Location: Home > Phospho Antibodies > NFκB-p100(Phospho-Ser870) Antibody

NFκB-p100(Phospho-Ser870) Antibody#11016

Availability: Yes
Total Amount:$
Product Detail

Product NameNFκB-p100(Phospho-Ser870) Antibody

Host SpeciesRabbit

ClonalityPolyclonal

PurificationAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.

ApplicationsWB IHC IF

Species ReactivityHu Ms Rt

SpecificityThe antibody detects endogenous level of NFκB-p100 only when phosphorylated at serine 870.

Immunogen TypePeptide-KLH

Immunogen DescPeptide sequence around phosphorylation site of serine 870(Y-G-S(p)-Q-S) derived from Human NFκB-p100.

Target NameNFκB-p100

ConjugateUnconjugated

Other Namesp52; p105; H2TF1; LYT10; NF-kB2

Accession NoSwiss-Prot: Q00653
NCBI Gene ID: 4791
NCBI mRNA: NM_001077494.2
NCBI Protein: NP_001070962.1

Uniprot Q00653

Gene ID 4791;

Concentration1.0mg/ml

FormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

StorageStore at -20°C

Application Details
 Predicted MW: 120kd
Western blotting: 1:500
Immunohistochemistry: 1:50~1:100
Immunofluorescence: 1:100~1:200
Immunofluorescence staining of methanol-fixed HeLa cells using NF-κB p100(phospho-Ser870) antibody (#11016, Red).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NF-κB p100(phospho- Ser870) antibody (#11016).
Western blot analysis of extract from MDA-MB-435 cells untreated or treated with TNF-α (20ng/ml, 5min) using NF-κB p100(phospho-Ser870) antibody (#11016).
All lanes : NFκB-p100(Phospho-Ser870) Antibody Antibody at 1/500 dilution

Lane 1 : Hela whole cell lysates
Lane 2 : Hela treated with 20ng/ml TNFa for 15min whole cell lysates

Lane 3 : Hela treated with 50ng/ml IL-2 for 15min whole cell lysates
Lane 4 : K562 whole cell lysates
Lane 5 : K562 treated with 20ng/ml TNFa for 15min whole cell lysates
Lane 6 : K562 treated with 50ng/ml IL-2 for 15min whole cell lysates
Lysates/proteins at 20 µg per lane.

Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) at 1/20000 dilution

Predicted band size: 97 kDa
Observed band size: 97 kDa

Exposure time: 6 seconds
All lanes : NFκB-p100(Phospho-Ser870) Antibody Antibody at 1/500 dilution

Lane 1 : Mouse liver lysates
Lane 2 : Rat liver lysates
Lane 3 : Rat kidney lysates
Lysates/proteins at 20 µg per lane.

Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) at 1/20000 dilution

Predicted band size: 97 kDa
Observed band size: 97 kDa

Exposure time: 7 seconds

 NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.

Dobrzanski P., Ryseck R.P., Bravo R.EMBO J. 13:4608-4616(1994)

Betts J.C., Nabel G.J.Mol. Cell. Biol. 16:6363-6371(1996)

If you have published an article using product 11016, please notify us so that we can cite your literature.

NOTE

Application

  • WBWestern Blotting
  • IHCImmunohistochemistry
  • IFImmunofluorescence
  • ICCImmunocytochemistry
  • FCFlow Cytometry
  • IPImmunoprecipitation
  • EELISA
  • DBDot Blotting
  • ChIPChromatin Immunoprecipitation
  • GICAGold Immunochromatography Assay
  • NCNegative Control

Species Reactivity

  • HuHuman
  • MsMouse
  • RtRat
  • DmDrosophila melanogaster
  • CCaenorhabditis elegans
  • MkMonkey
  • RbRabbit
  • BBovine
  • DDog
  • PPig
  • HmHamster
  • ChHmChinese Hamster
  • ChkChicken
  • ShpSheep
;